Trial record 1 of 1 for:    NCT00291226
Previous Study | Return to List | Next Study

Glycine vs Placebo for the Schizophrenia Prodrome

This study has been completed.
Glytech, Inc
National Alliance for Research on Schizophrenia and Depression
Information provided by:
Yale University Identifier:
First received: February 10, 2006
Last updated: January 13, 2010
Last verified: January 2010

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Condition Intervention Phase
Schizophrenia Prodrome
Drug: Glycine
Drug: Placebo
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Glycine vs Placebo for the Schizophrenia Prodrome

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Scale of Prodromal Symptoms total score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]

Enrollment: 8
Study Start Date: March 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Glycine
Glycine 0.4 g/kg bid
Placebo Comparator: 2
Drug: Placebo


Ages Eligible for Study:   13 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • meet SIPS criteria for schizophrenia prodrome

Exclusion Criteria:

  • history of psychosis
  Contacts and Locations
Please refer to this study by its identifier: NCT00291226

United States, Connecticut
PRIME Clinic
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
Glytech, Inc
National Alliance for Research on Schizophrenia and Depression
Principal Investigator: Scott W Woods, MD Yale School of Medicine
  More Information

No publications provided by Yale University

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Scott Woods, Yale University School of Medicine Identifier: NCT00291226     History of Changes
Other Study ID Numbers: Glytech, NARSAD Distinguished 2005
Study First Received: February 10, 2006
Last Updated: January 13, 2010
Health Authority: United States: Food and Drug Administration

Keywords provided by Yale University:
schizophrenia prodrome

Additional relevant MeSH terms:
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Glycine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs processed this record on April 16, 2014